Close this search box.

Adium Pharma reaches an important agreement with Moderna Inc. to collaborate in the distribution and commercialization of covid 19 vaccines in Latin America

Leading company in pharmaceutical innovation, headquartered in our country, signs an unprecedented agreement for the arrival of COVID-19 vaccines Montevideo, Uruguay. February 21, 2022 ADIUM Pharma and Moderna Inc. reached an agreement for the distribution and commercialization throughout Latin America for SPIKEVAX, the vaccine developed by Moderna against SARS-CoV-2. ADIUM is a leading pharmaceutical company […]

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

May 19, 2021 NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into an exclusive distribution agreement with Adium Pharma S.A. […]

PharmaMar signs a new agreement with ADIUM PHARMA S.A. to commercialize Yondelis® in Latin America

PharmaMar will receive an upfront payment and is eligible for additional remunerations, including regulatory milestone payments. Madrid, July 27th, 2020. – PharmaMar (MSE:PHM) has announced today a licensing agreement with ADIUM Pharma S.A. to commercialize the marine-derived anticancer drug Yondelis® (trabectedin) in Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Curacao, Dominican Republic, Ecuador, El Salvador, […]

We use cookies on our website to provide you the most relevant experience by remembering your preferences and repeat visits. By Clicking "Accept", you agree to the use of all cookies.